FDA Clears Roche Blood Test for Alzheimer’s

New blood-based tools are making it easier to detect biological signs of Alzheimer’s disease earlier, while researchers increasingly explore treatment before symptoms appear. Roche’s FDA-cleared Elecsys pTau217 test is intended for adults with cognitive concerns and can help clinicians assess whether amyloid pathology is likely or unlikely, potentially reducing reliance on costly brain scans or spinal taps, though it does not replace a full diagnostic evaluation. An NIH-funded study of 1,350 adults in their 50s and 60s found that higher blood levels of Alzheimer’s-related tau and amyloid forms were associated with greater cognitive decline over five years, but researchers say the tests need further validation before routine use. Separately, a multinational trial enrolling 1,600 symptom-free adults with Alzheimer’s biomarkers is testing whether trontinemab can clear amyloid before neurological damage develops. Together, the advances reflect a shift toward earlier diagnosis and prevention, while questions remain about test accuracy, appropriate clinical use and whether preventive treatments can delay disease.